Navigation Links
Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
Date:11/14/2007

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, and the potential of microRNAs in the diagnosis and treatment of disease, and the expected progress and timing of the liver cancer therapeutic program constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover and develop novel diagnostics and therapeutic products, which is unproven and may never lead to marketable products; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta's ability to successfully develop its product candidates, all of which are in early stages of development; Rosetta's ability to obtain regulatory approval for products; competition from others using technology similar to Rosetta's and others developing products for similar uses; Rosetta's dependence on collaborators; and Rosetta's short operating history; as well as those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of the
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
8. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
9. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
10. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
11. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... A major challenge before new biotechnology start-up ... of Boston-Cambridge, is gaining visibility that can lead to ... Director of Boston’s Adult Stem Cell Technology Center, LLC ... of his company an important priority since he started ... a social media marketing campaign launched earlier ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... an alcohol-based hand sanitizer, asks food processors and food ... the hand sanitizer they’re currently using to Best Sanitizers’ ... hygiene is critical to fighting cross-contamination and the spread ... Sanitizers believes there are key criteria that make a ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... Funding Milestone Continues Progress at Seneca, Illinois ... ... NBF ) announced today that it has satisfied the conditions ... million,senior secured credit facility with WestLB AG, one of the world,s ...
... Phase 2b Trial Expected to Begin in the ... 4 Mpex Pharmaceuticals, Inc. today,announced that the ... Products Development has granted Mpex orphan drug designation ... pulmonary,infections due to Pseudomonas aeruginosa and other bacteria ...
... the Chinese Pharmaceutical ... CHENGDU, China, March 4 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, ... and,supplier of modernized traditional Chinese medicine ("TCM") based ... members:,Professor Zunjian Zhang, Ph.D., Professor Jianping Hou, Ph.D. ...
Cached Biology Technology:Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 2Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 2Tianyin Pharmaceutical Appoints Three New Independent Board Members 3Tianyin Pharmaceutical Appoints Three New Independent Board Members 4
(Date:8/28/2014)... A free mobile app called TX Invasives is now ... The University of Texas at Austin for identifying harmful ... , Invasive species in the United States cause about ... they destroy agricultural crops, clog waterways, kill native plants ... TX Invasives app for reporting where invasive species occur, ...
(Date:8/28/2014)... German . ... to a striking pattern of blue stripes alternating with golden ... cells, and yellow cells emerge during growth in the skin ... mosaic to compose the characteristic colour pattern. ,While ... interact to form proper stripes, the embryonic origin of the ...
(Date:8/28/2014)... 2014) Researchers at the University of Minnesota have ... (FSHD) to be used for muscle regeneration research as ... for FSHD. , The research is published in the ... , There is no treatment for FSHD, which is ... of muscular dystrophy. FSHD is an unusual genetic disorder ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3UMN researchers find animal model for understudied type of muscular dystrophy 2
... The tummy,s taste for red wine with red meat , ... happens when red wine meets red meat? If the rendezvous ... bounty of healthful chemical compounds may thwart formation of harmful ... study, which reinforces the benefits of consuming wine and other ...
... closer to understanding the recent demise of billions of honey ... a common bee virus. Deformed wing virus (DWV) is passed ... parasitic mite called Varroa destructor when it feeds. However, research ... General Virology suggests that the virus does not replicate ...
... of Crohn,s disease researchers has combined data from ... variants associated with the inflammatory bowel disorder, bringing ... Several of these are involved with the ... evidence that disruptions in a process called autophagy ...
Cached Biology News:American Chemical Society's Weekly PressPac -- June 25, 2008 2American Chemical Society's Weekly PressPac -- June 25, 2008 3American Chemical Society's Weekly PressPac -- June 25, 2008 4American Chemical Society's Weekly PressPac -- June 25, 2008 5American Chemical Society's Weekly PressPac -- June 25, 2008 6American Chemical Society's Weekly PressPac -- June 25, 2008 7American Chemical Society's Weekly PressPac -- June 25, 2008 8American Chemical Society's Weekly PressPac -- June 25, 2008 9Bee disease a mystery 2International team identifies 21 new genetic risk factors for Crohn's disease 2
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
... PGE2-d4 contains 4 deuterium atoms at ... It is intended for use as an ... E2 (PGE2) by GC- or LC-mass spectrometry. ... products of arachidonic acid and one of ...
, Glycerol 30%...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Biology Products: